171 related articles for article (PubMed ID: 36788940)
1. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension.
Kuwana M; Abe K; Kinoshita H; Matsubara H; Minatsuki S; Murohara T; Sakao S; Shirai Y; Tahara N; Tsujino I; Takahashi K; Kanda S; Ogo T
Pulm Circ; 2023 Jan; 13(1):e12198. PubMed ID: 36788940
[TBL] [Abstract][Full Text] [Related]
2. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
3. Inhaled treprostinil: a therapeutic review.
Channick RN; Voswinckel R; Rubin LJ
Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
[TBL] [Abstract][Full Text] [Related]
5. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
6. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
7. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.
Zamanian RT; Levine DJ; Bourge RC; De Souza SA; Rosenzweig EB; Alnuaimat H; Burger C; Mathai SC; Leedom N; DeAngelis K; Lim A; De Marco T
Pulm Circ; 2016 Sep; 6(3):329-37. PubMed ID: 27683610
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
12. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).
Hill NS; Feldman JP; Sahay S; Benza RL; Preston IR; Badesch D; Frantz RP; Patel S; Galloway A; Bull TM;
Pulm Circ; 2022 Jul; 12(3):e12119. PubMed ID: 36034402
[TBL] [Abstract][Full Text] [Related]
13. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Spikes LA; Bajwa AA; Burger CD; Desai SV; Eggert MS; El-Kersh KA; Fisher MR; Johri S; Joly JM; Mehta J; Palevsky HI; Ramani GV; Restrepo-Jaramillo R; Sahay S; Shah TG; Deng C; Miceli M; Smith P; Shapiro SM
Pulm Circ; 2022 Apr; 12(2):e12063. PubMed ID: 35514770
[TBL] [Abstract][Full Text] [Related]
14. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension.
Takatsuki S; Parker DK; Doran AK; Friesen RH; Ivy DD
Pediatr Cardiol; 2013 Apr; 34(4):1006-12. PubMed ID: 23184020
[TBL] [Abstract][Full Text] [Related]
15. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
Ferrantino M; White RJ
Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension.
Enderby CY; Burger C
Ther Adv Chronic Dis; 2018 Sep; 9(9):171-177. PubMed ID: 30181846
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
19. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD
N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.
Buckley MS; Berry AJ; Kazem NH; Patel SA; Librodo PA
Core Evid; 2014; 9():71-80. PubMed ID: 25018685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
